论文部分内容阅读
[目的]探讨榄香烯、丝裂霉素C、NDV对HCa-F和L615瘤细胞生物学性状的影响。[方法]将HCa-F、L615细胞分别用50μg/mL或100μg/mL榄香烯(elem ene,E)、50μg/mL丝裂霉素(m itomyc in C,MMC)处理,未处理的细胞为对照组,观察细胞存活率;电镜观察超微结构的改变;将HCa-F、L615瘤细胞处理后,流式细胞仪观察凋亡和细胞周期的变化。[结果]HCa-F细胞在50μg/mL E处理的0~6 h,存活率从(99.8±0.2)%变为(30.8±5.8)%,100μg/mL E处理2 h时已无存活的HCa-F细胞(P<0.01);L615细胞经50μg/mL E处理2 h,存活率即为0(P<0.01)。在HCa-F细胞内可见染色体边集、核固缩及凋亡小体;L615细胞各组凋亡细胞率分别为(17.70±0.85)%,(32.72±1.32)%,(55.13±1.09)%(P<0.01),而HCa-F细胞凋亡率分别为(2.15±0.08)%、(3.76±0.34)%、(5.60±0.57)%、(8.00±1.20)%(P<0.01);E单独处理L615细胞时其S期细胞百分率增加为(45.6±8.9)%(P<0.01),但单用MMC或E-MMC复合处理却使L615细胞的S期比率减少为0(P<0.01)。[结论]榄香烯与丝裂霉素C在细胞毒效应方面存在协同作用,使肿瘤细胞阻滞在S期,减少进入G2-M期的细胞数目。
[Objective] To investigate the effects of elemene, mitomycin C and NDV on the biological characteristics of HCa-F and L615 tumor cells. [Method] HCa-F and L615 cells were treated with 50 μg / mL or 100 μg / mL elem ene (E) and 50 μg / mL mitomycin C (MMC) respectively. Untreated cells As the control group, the survival rate of the cells was observed. The changes of the ultrastructure were observed by electron microscopy. The apoptosis and cell cycle of the HCa-F and L615 tumor cells were observed by flow cytometry. [Results] The survival rate of HCa-F cells from (99.8 ± 0.2)% to (30.8 ± 5.8)% at 0 ~ 6 h after 50 μg / mL E treatment had no viable HCa at 100 μg / mL E -F cells (P <0.01). The survival rate of L615 cells treated with 50 μg / mL E for 2 h was 0 (P <0.01). In the HCa-F cells, the chromosome edge set, nuclear condensation and apoptotic bodies were observed. The apoptotic cells in L615 cells were (17.70 ± 0.85)%, (32.72 ± 1.32)%, (55.13 ± 1.09)% (2.15 ± 0.08)%, (3.76 ± 0.34)%, (5.60 ± 0.57)%, (8.00 ± 1.20)%, respectively (P <0.01) The percentage of S phase cells increased (45.6 ± 8.9)% (P <0.01) in L615 cells treated with MMC or E-MMC alone, but the S phase ratio of L615 cells decreased to 0 (P <0.01) . [Conclusion] Elemene and mitomycin C have a synergistic effect on the cytotoxic effect, which makes tumor cells arrest in S phase and reduce the number of cells entering G2-M phase.